DEA Proposes Changes to Drug Quota Applications
Published Date: 5/20/2026
Proposed Rule
Summary
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 3 costs, 1 mixed.
New Quota Application Timeline Reporting
If you are a bulk or non-bulk manufacturer applying for DEA quotas, you must provide new production-timeline details on quota applications (DEA Form 189 for bulk manufacturers; DEA Form 250 for non-bulk manufacturers). DEA lists the required items: desired individual manufacturing quota (bulk only), time to start production after receiving DEA's quota letter, time to receive API after quota letter (procurement), time to perform the production cycle, time to ship finished goods to the next registrant, supplier of the basic class/chemical (if from another registrant), and any additional relevant factors.
Better Data to Prevent Drug Shortages
DEA says the new application information and subcategory changes will give the agency better visibility into manufacturing cycles and domestic vs. export use, enabling DEA to adjust quotas more quickly to anticipate and help prevent drug shortages that affect medical and scientific needs.
Domestic vs. Export Quota Split
DEA will split certain quota subcategories so manufacturers must state whether quota is for domestic use or for lawful export. The rule bifurcates 'Quota for Commercial Sale', 'Quota for Product Development', and 'Quota for Packaging/Repackaging and Labeling/Relabeling' into domestic and export subcategories (e.g., 'Quota for Domestic Commercial Sale' and 'Quota for Commercial Manufacturing for Export').
Estimated Time and Dollar Burden
DEA estimates the new information will add about 20 minutes per DEA Form 189 or 250 to complete, with a loaded median hourly cost of $89.42 for a purchasing manager, producing an estimated per-application cost of $29.81. Using 2022 application counts (875 Form 189 and 2,514 Form 250), DEA estimates an annual total cost of $101,026.
Small-Entity Impact Finding
DEA certifies under the Regulatory Flexibility Act that the proposed rule will not have a significant economic impact on a substantial number of small entities. DEA estimates the rule would affect 38 of 635 small entities in NAICS 325411 and 272 of 1,080 small entities in NAICS 325412, with estimated economic impacts of 0.095% and 0.022% of annual receipts for those industries, respectively.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08517 — Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
Starting May 1, 2026, the DEA officially puts four new substances—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I, meaning they’re now illegal to make, sell, or use without special permission. This affects anyone handling these chemicals, including researchers and businesses, who must follow strict rules or face serious penalties. The move aims to keep communities safer by cracking down on these risky drugs.